« Previous Next »Gastrointestinal Endoscopy
Volume 71, Issue 2 , Pages 235-240, February 2010

Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?

Presented at the 2009 Gastrointestinal Cancers Symposium, January 13-15, San Francisco, California.

Received 4 July 2009; accepted 25 September 2009. published online 09 December 2009.

Tampa, Florida, USA

Background

Adenocarcinoma of the esophagus is frequently associated with Barrett's esophagus (BE). The response of esophageal adenocarcinoma to chemoradiation therapy is well described; however, the effect of chemoradiation on tumor-associated BE has not been specifically reported.

Objective

To determine the response of tumor-associated BE to chemoradiation therapy.

Design

Retrospective cohort study.

Setting

A single National Cancer Institute Comprehensive Cancer Care Center experience.

Patients

The study cohort consisted of 43 patients with stage I to IVA esophageal adenocarcinoma associated with BE who received either neoadjuvant or definitive chemoradiation therapy and underwent either esophagectomy or surveillance at our institution.

Main Outcome Measurement

The presence and extent of BE after chemoradiation therapy of esophageal adenocarcinoma associated with endoscopically documented pretreatment BE.

Results

BE persisted after chemoradiation therapy in 93% (40/43) of cases (95% CI, 83%-99%). Twenty-seven patients received neoadjuvant chemoradiation therapy before esophagectomy. Persistent BE was detected in all 27 surgical specimens (100%). In 59% (16/27) of the cases, there was complete pathologic tumor response. Sixteen patients received definitive chemoradiation therapy. Persistent pretreatment BE was identified in 88% (14/16) by surveillance endoscopy (95% CI, 60%-98%). The mean length of BE before and after chemoradiation was 6.6 cm and 5.8 cm, respectively (P = .38).